Trial Details

COMPLETED
Basic Information
Clinical ID c1863
Identifier NCT03629379
Trial Title Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions
Trial URL Visit Original Page
Study Information
Study Results

NO

Conditions Inflammatory Bowel Diseases; Psoriasis
Interventions DRUG: Ustekinumab; DRUG: Vedolizumab
Participant Information
Sponsor Universitaire Ziekenhuizen KU Leuven
City Leuven
Country/Region Belgium
Enrollment Criteria
Sex Requirement ALL
Age Requirement -
Study Design
Study Type INTERVENTIONAL
Phase PHASE4
Time Information
Start Date 2019-01-22
Primary Completion Date 2021-01-01
Completion Date 2021-07-01